Combination antithrombotic therapy in acute myocardial infarction. 2002

Thomas L Rihn, and Gordon J Vanscoy
Duquesne University School of Pharmacy, Pittsburgh, PA, USA. trihn@upa-llc.com

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003328 Coronary Thrombosis Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION. Thrombosis, Coronary,Coronary Thromboses,Thromboses, Coronary
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

Thomas L Rihn, and Gordon J Vanscoy
February 2003, Current treatment options in cardiovascular medicine,
Thomas L Rihn, and Gordon J Vanscoy
June 1995, Journal of the American College of Cardiology,
Thomas L Rihn, and Gordon J Vanscoy
September 2008, Der Internist,
Thomas L Rihn, and Gordon J Vanscoy
December 1988, Journal of the American College of Cardiology,
Thomas L Rihn, and Gordon J Vanscoy
August 1999, American heart journal,
Thomas L Rihn, and Gordon J Vanscoy
December 1999, Journal of the American College of Cardiology,
Thomas L Rihn, and Gordon J Vanscoy
September 1982, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
Thomas L Rihn, and Gordon J Vanscoy
April 1998, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Thomas L Rihn, and Gordon J Vanscoy
September 2002, The New England journal of medicine,
Thomas L Rihn, and Gordon J Vanscoy
April 1998, Archives des maladies du coeur et des vaisseaux,
Copied contents to your clipboard!